Form 4: Akari Therapeutics Director Acquires Shares and Warrants in Private Placement

Raymond Prudo-Chlebosz, a director of Akari Therapeutics Plc, acquired shares and warrants in a private placement on March 6, 2025.

Summary

• On March 6, 2025, Raymond Prudo-Chlebosz, a director of Akari Therapeutics Plc, acquired 446,428 American Depositary Shares (ADS) and accompanying Series A and Series B warrants.
• The purchase was made through a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.
• The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.
• Following the transaction, Prudo-Chlebosz directly owns 446,428 ADS and indirectly owns 19,355 ADS through Praxis Trustees Limited and 400,383 ADS through RPC Pharma Limited.
• The Series A and Series B warrants allow the purchase of up to 892,856 ADS at an exercise price of $0.87.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction by a company director. The director's purchase could be seen as a positive signal, but it's not overwhelmingly so.

Positives

• A director's investment in the company may signal confidence in its future prospects.

Industry Context

Director's transactions are routinely monitored by investors as they can provide insights into the insider's perspective on the company's valuation and future performance.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive sign, potentially increasing investor confidence.

Key Dates